Zydus Cadila receives FDA nod for generic Rythmol
Zydus Cadila's generic Rythmol capsules work by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.
The Food and Drug Administration has given Zydus Cadila its stamp of approval for propafenone hydrochloride extended release capsules, in dosage strengths of 225 mg, 325 mg, and 425 mg.
The product is the generic of Rythmol capsules.
It is an anti-arrhythmic drug, which works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.
The drug will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.